Relapse status in patients with BOR of CR/CRi
| . | All patients (N = 497) . | ≥18 years (n = 149) . | <18 years (n = 348) . | <3 years (n = 31) . |
|---|---|---|---|---|
| Ongoing remission∗ | 189 (38.0) | 56 (37.6) | 133 (38.2) | 9 (29.0) |
| Patients censored by therapy | ||||
| allo-SCT | 96 (19.3) | 28 (18.8) | 68 (19.5) | 11 (35.5) |
| Tisagenlecleucel reinfusion | 47 (9.5) | 9 (6.0) | 38 (10.9) | 3 (9.7) |
| Other CAR T-cell therapy | 6 (1.2) | 1 (0.7) | 5 (1.4) | 0 |
| Other cell therapy | 3 (0.6) | 2 (1.3) | 1 (0.3) | 0 |
| Death | 13 (2.6) | 9 (6.0) | 4 (1.1) | 0 |
| Relapse | 143 (28.8) | 44 (29.5) | 99 (28.4) | 8 (25.8) |
| CD19+ | 46 (32.2) | 18 (40.9) | 28 (28.3) | 1 (12.5) |
| Previous blinatumomab | 14 (30.4) | 9 (50.0) | 5 (17.9) | 0 |
| CD19– | 37 (25.9) | 9 (20.5) | 28 (28.3) | 5 (62.5) |
| Previous blinatumomab | 7 (18.9) | 4 (44.4) | 3 (10.7) | 0 |
| CD19 unknown | 60 (42.0) | 17 (38.6) | 43 (43.4) | 2 (25.0) |
| Previous blinatumomab | 15 (25.0) | 4 (23.5) | 11 (25.6) | 1 (50.0) |
| . | All patients (N = 497) . | ≥18 years (n = 149) . | <18 years (n = 348) . | <3 years (n = 31) . |
|---|---|---|---|---|
| Ongoing remission∗ | 189 (38.0) | 56 (37.6) | 133 (38.2) | 9 (29.0) |
| Patients censored by therapy | ||||
| allo-SCT | 96 (19.3) | 28 (18.8) | 68 (19.5) | 11 (35.5) |
| Tisagenlecleucel reinfusion | 47 (9.5) | 9 (6.0) | 38 (10.9) | 3 (9.7) |
| Other CAR T-cell therapy | 6 (1.2) | 1 (0.7) | 5 (1.4) | 0 |
| Other cell therapy | 3 (0.6) | 2 (1.3) | 1 (0.3) | 0 |
| Death | 13 (2.6) | 9 (6.0) | 4 (1.1) | 0 |
| Relapse | 143 (28.8) | 44 (29.5) | 99 (28.4) | 8 (25.8) |
| CD19+ | 46 (32.2) | 18 (40.9) | 28 (28.3) | 1 (12.5) |
| Previous blinatumomab | 14 (30.4) | 9 (50.0) | 5 (17.9) | 0 |
| CD19– | 37 (25.9) | 9 (20.5) | 28 (28.3) | 5 (62.5) |
| Previous blinatumomab | 7 (18.9) | 4 (44.4) | 3 (10.7) | 0 |
| CD19 unknown | 60 (42.0) | 17 (38.6) | 43 (43.4) | 2 (25.0) |
| Previous blinatumomab | 15 (25.0) | 4 (23.5) | 11 (25.6) | 1 (50.0) |
Efficacy set. Data are presented as n (%).
With censoring for allo-SCT.